Clinical Trial Search

Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients

Primary: Change in Montgomery Asberg Depression Rating Scale (MADRS)-6 Score Using Average of Changes From Baseline to Week 3 Through the End of Treatment Period (Week 5 for…

Primary: Comparison of E-C and Inhalator in Effects on Withdrawal Over 24 Hours of Use. — 0.73; 0.86 units on a scale — p=0.17

Primary: Number of Subjects With Adverse Events (AEs) — 27; 28 Participants

Primary: Feasibility and Safety Using an Improved, More Efficient and Less Labor Intensive Cooling Balloon in Patients Undergoing Hypothermic Nerve-sparing RLP in Participants…

Primary: Neutrophil Oxidative Burst Activity — 302; 302; 298; 268 Median Fluorescence Intensity — p=0.56

Primary: Glycosylated Haemoglobin — 8.36; 8.16; 8.23; 8.53 percentage of glycosylated hemoglobin

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 86.6; 94.1 percentage of participants

Primary: Maximum Observed Concentration (Cmax) of Pyrimethamine in Healthy Japanese Male Participants — 430.5 Nanogram per milliliter

Primary: Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 16 Weeks of Treatment. — 0.00; -0.92; -1.00 percentage of HbA1c — p=<0.0001

Primary: Evans Grade Histopathologic Response — 10; 7; 17; 12 number of participants

Primary: Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection With Either CYD Dengue…

Primary: Pain Measurement Via VAS (Visual Analog Scale) — 4.11; 4.68; 4.36 score on a scale

Primary: The Change From Baseline to the End of Treatment Period in Maximum Dysmenorrheic Pain VAS Score — -19.8; -18.0; -14.4 units on a scale — p=>0.05

Primary: Proportion of Patients With Target Adverse Events for the Step 2 Treatment — 0.03 proportion of participants